

174. (Amended) A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, the method comprising contacting a multi-epitopic *in vivo* antigen present in a host's serum with a composition comprising a binding agent that specifically binds to an epitope on the antigen, the binding agent present in the composition being non-radiolabeled, and allowing the binding agent to form a binding agent/antigen complex, wherein the binding agent/antigen complex elicits an effective host immune response against the multi-epitopic *in vivo* antigen.

G3G2

207. (Amended) The method of claim 201, wherein the composition is administered by any immunologically suitable route.

Please add the following new claims.

CA Sur GZ

- 210. (New) A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, comprising administering to the host a composition comprising the antigen and a binding agent that specifically binds to an epitope on the antigen, thereby forming a binding agent/antigen pair, whereby an effective host immune response is elicited against the antigen.
- 211. (New) The method of claim 210, wherein the antigen is a soluble antigen.
- 212. (New) The method of claim 210, wherein the antigen is a tumor antigen.
- 213. (New) The method of claim 212, wherein the antigen is a soluble tumor antigen.
- 214. (New) The method of claim 211, wherein the soluble antigen is associated with a human disease or condition.
- 215. (New) The method of claim 214, wherein the human disease or condition is cancer.
- 216. (New) The method of claim 210, wherein the composition is administered by any immunologically suitable route.

Sub G2

- 217. (New) The method of claim 216, wherein administering by any immunologically suitable route comprises intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.
- 218. (New) The method of claim 216, wherein administering by any immunologically suitable route comprises administering in solution, tablet, or aerosol form.
- 219. (New) The method of claim 210, wherein the composition comprising a binding agent further comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more imaging reagents, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.
- 220. (New) The method of claim 210, wherein the effective host immune response is elicited against an epitope on the binding agent/antigen complex.
- 221. (New) The method of claim 210, wherein the effective host immune response comprises a cellular and humoral immune response.
- 222. (New) The method of claim 210, wherein the effective host immune response comprises a cellular immune response.
- 223. (New) The method of claim 210, wherein the effective host immune response comprises a humoral immune response.
- 224. (New) The method of claim 220, wherein the binding agent is an antibody.
- 225. (New) The method of claim 224, wherein the antibody is a murine monoclonal antibody.
- 226. (New) The method of claim 224, wherein the antibody does not induce isotypic HAMA-induced toxicity in the host.
- 227. (New) The method of claim 210, wherein the binding agent is B43.13.
- 228. (New) The method of claim 210, wherein the binding agent has been exposed to ultraviolet radiation.